前列腺癌中存在缺陷的DNA修复机制：奥拉帕尼的影响
Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
作者信息
De Felice Francesca, Tombolini Vincenzo, Marampon Francesco, Musella Angela, Marchetti Claudia
机构信息
Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome.
Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila.
出版信息
Drug Des Devel Ther. 2017 Mar 1;11:547-552. doi: 10.2147/DDDT.S110264. eCollection 2017.
Abstract
The field of prostate oncology has continued to change dramatically. It has truly become a field that is intensely linked to molecular genetic alterations, especially DNA-repair defects. Germline breast cancer 1 gene (BRCA1) and breast cancer 2 gene (BRCA2) mutations are implicated in the highest risk of prostate cancer (PC) predisposition and aggressiveness. Poly adenosine diphosphate ribose polymerase (PARP) proteins play a key role in DNA repair mechanisms and represent a valid target for new therapies. Olaparib is an oral PARP inhibitor that blocks DNA repair pathway and coupled with BRCA mutated-disease results in tumor cell death. In phase II clinical trials, including patients with advanced castration-resistant PC, olaparib seems to be efficacious and well tolerated. Waiting for randomized phase III trials, olaparib should be considered as a promising treatment option for PC.
摘要
前列腺肿瘤学领域一直在发生巨大变化。它已真正成为一个与分子遗传改变紧密相关的领域，尤其是DNA修复缺陷。种系乳腺癌1基因（BRCA1）和乳腺癌2基因（BRCA2）突变与前列腺癌（PC）易感性和侵袭性的最高风险相关。聚腺苷二磷酸核糖聚合酶（PARP）蛋白在DNA修复机制中起关键作用，是新疗法的有效靶点。奥拉帕利是一种口服PARP抑制剂，可阻断DNA修复途径，与BRCA突变疾病结合会导致肿瘤细胞死亡。在包括晚期去势抵抗性PC患者的II期临床试验中，奥拉帕利似乎有效且耐受性良好。在等待随机III期试验结果期间，奥拉帕利应被视为PC的一种有前景的治疗选择。
相似文献
1
Defective DNA repair mechanisms in prostate cancer: impact of olaparib.前列腺癌中存在缺陷的DNA修复机制：奥拉帕尼的影响
Drug Des Devel Ther. 2017 Mar 1;11:547-552. doi: 10.2147/DDDT.S110264. eCollection 2017.
2
A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌的新用途。
Pharmacotherapy. 2017 Nov;37(11):1406-1414. doi: 10.1002/phar.2027.
3
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.胚系BRCA1/2突变的晚期卵巢癌患者对PARP抑制剂奥拉帕尼抗肿瘤反应的基线临床预测指标。
Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.
4
Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.奥拉帕利治疗 BRCA 突变型晚期卵巢癌。
Am J Health Syst Pharm. 2016 Jul 15;73(14):1037-41. doi: 10.2146/ajhp150550.
5
DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.DNA修复缺陷在晚期前列腺癌中常见：新的治疗机遇
Oncologist. 2016 Aug;21(8):940-5. doi: 10.1634/theoncologist.2016-0135. Epub 2016 Jun 17.
6
Olaparib for the treatment of breast cancer.奥拉帕利用于治疗乳腺癌。
Expert Opin Investig Drugs. 2017 Jun;26(6):751-759. doi: 10.1080/13543784.2017.1318847. Epub 2017 Apr 21.
7
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).在伴有 DNA 修复缺陷的一线转移性去势抵抗性前列腺癌（BRCAAway）中，阿比特龙、奥拉帕利或阿比特龙+奥拉帕利。
Clin Cancer Res. 2024 Oct 1;30(19):4318-4328. doi: 10.1158/1078-0432.CCR-24-1402.
8
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.转移性前列腺癌中的DNA修复缺陷与奥拉帕利
N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.
9
Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.奥拉帕利治疗 BRCA 缺陷型复发性上皮性卵巢癌的研究进展。
Clin Cancer Res. 2015 Sep 1;21(17):3829-35. doi: 10.1158/1078-0432.CCR-15-0088. Epub 2015 Jul 13.
10
Advances in PARP inhibitors for the treatment of breast cancer.用于治疗乳腺癌的PARP抑制剂的进展
Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20.
引用本文的文献
1
PARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer.聚（ADP-核糖）聚合酶（PARP）抑制剂奥拉帕利可诱导DNA损伤，并在犬类造血癌的体外模型中作为一种药物增敏剂发挥作用。
BMC Vet Res. 2025 Jul 5;21(1):439. doi: 10.1186/s12917-025-04880-z.
2
Evaluative Methodology for HRD Testing: Development of Standard Tools for Consistency Assessment.人力资源开发测试的评估方法：用于一致性评估的标准工具的开发。
Genomics Proteomics Bioinformatics. 2025 May 10;23(1). doi: 10.1093/gpbjnl/qzaf017.
3
Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Controlled Trial-Based Network Meta-Analysis.转移性激素敏感性前列腺癌的系统治疗：一项基于随机对照试验的网络荟萃分析。
J Oncol. 2022 Jun 29;2022:7711555. doi: 10.1155/2022/7711555. eCollection 2022.
4
Double-strand DNA break repair: molecular mechanisms and therapeutic targets.双链DNA断裂修复：分子机制与治疗靶点
MedComm (2020). 2023 Oct 5;4(5):e388. doi: 10.1002/mco2.388. eCollection 2023 Oct.
5
Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.前列腺癌中的谱系可塑性和治疗耐药性：遗传学、表观遗传学和进化的交集。
Front Endocrinol (Lausanne). 2023 Jun 30;14:1191311. doi: 10.3389/fendo.2023.1191311. eCollection 2023.
6
Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies.合成与天然化合物作为新型组蛋白去乙酰化酶抑制剂治疗血液系统恶性肿瘤的潜力
Cancers (Basel). 2023 May 17;15(10):2808. doi: 10.3390/cancers15102808.
7
SLC26A4 correlates with homologous recombination deficiency and patient prognosis in prostate cancer.SLC26A4 与同源重组缺陷和前列腺癌患者预后相关。
J Transl Med. 2022 Jul 14;20(1):313. doi: 10.1186/s12967-022-03513-5.
8
Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing.伴有BRCA2突变的转移性去势抵抗性前列腺癌：在治疗顺序中纳入PARP抑制剂和铂类药物的挑战
Eur J Case Rep Intern Med. 2022 May 24;9(5):003331. doi: 10.12890/2022_003331. eCollection 2022.
9
HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer.具有克服去势抵抗性前列腺癌耐药潜力的组蛋白去乙酰化酶抑制剂
Cancer Drug Resist. 2022 Jan 4;5(1):64-79. doi: 10.20517/cdr.2021.105. eCollection 2022.
10
Homologous Recombination Deficiency: Concepts, Definitions, and Assays.同源重组缺陷：概念、定义和检测。
Oncologist. 2022 Mar 11;27(3):167-174. doi: 10.1093/oncolo/oyab053.
本文引用的文献
1
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.奥拉帕利维持治疗铂敏感复发性浆液性卵巢癌期间的生活质量
Br J Cancer. 2016 Nov 22;115(11):1313-1320. doi: 10.1038/bjc.2016.348. Epub 2016 Nov 8.
2
PARP inhibitors and stratified treatment of prostate cancer.聚（ADP-核糖）聚合酶抑制剂与前列腺癌的分层治疗
Expert Rev Anticancer Ther. 2016 Dec;16(12):1213-1215. doi: 10.1080/14737140.2016.1243474. Epub 2016 Oct 17.
3
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.转移性前列腺癌男性患者的遗传性DNA修复基因突变
N Engl J Med. 2016 Aug 4;375(5):443-53. doi: 10.1056/NEJMoa1603144. Epub 2016 Jul 6.
4
DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.DNA修复缺陷在晚期前列腺癌中常见：新的治疗机遇
Oncologist. 2016 Aug;21(8):940-5. doi: 10.1634/theoncologist.2016-0135. Epub 2016 Jun 17.
5
PARP inhibition: A promising therapeutic target in ovarian cancer.聚（ADP-核糖）聚合酶抑制：卵巢癌中一个有前景的治疗靶点。
Cell Mol Biol (Noisy-le-grand). 2015 Oct 30;61(6):44-61.
6
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.转移性前列腺癌中的DNA修复缺陷与奥拉帕利
N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.
7
Integrative clinical genomics of advanced prostate cancer.晚期前列腺癌的整合临床基因组学
Cell. 2015 May 21;161(5):1215-1228. doi: 10.1016/j.cell.2015.05.001.
8
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.奥拉帕利单药治疗携带胚系 BRCA1/2 突变的晚期癌症患者。
J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.
9
Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.家族性前列腺癌病例中 DNA 修复基因的频发种系有害突变与疾病的进展相关。
Br J Cancer. 2014 Mar 18;110(6):1663-72. doi: 10.1038/bjc.2014.30. Epub 2014 Feb 20.
10
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.胚系 BRCA 突变与前列腺癌中淋巴结受累、远处转移和不良生存结局的风险增加相关。
J Clin Oncol. 2013 May 10;31(14):1748-57. doi: 10.1200/JCO.2012.43.1882. Epub 2013 Apr 8.
Zotero 插件